title: Aminosalicylates.
abstract: Aminosalicylates are the most common drugs for the primary treatment of inflammatory bowel disease. Various pro-drugs and formulations were developed in order to improve pharmacological profiles, optimize bioavailability and to gain highest efficacy in the treatment of ulcerative colitis (UC) and Crohn's disease. In vitro studies have greatly contributed to the understanding of the molecular actions in vivo and clinical studies have proven aminosalicylates to be effective and safe. This review summarizes the current knowledge on the molecular, pharmacological and clinical properties of aminosalicylates with respect to chemoprevention for UC-associated colorectal cancer.
authors: Christian Doppler Laboratory for Molecular Cancer Chemoprevention, Division of Gastroenterology and Hepatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, Austria.
authors: Christoph
authors: C
authors: Campregher
authors: Christoph
authors: C
authors: Gasche
mesh_terms: D000636:Aminosalicylic Acids / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016588:Anticarcinogenic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018890:Chemoprevention; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000473:pathology; D015179:Colorectal Neoplasms / Q000473:pathology / Q000517:prevention & control*; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000636:Aminosalicylic Acids; D000893:Anti-Inflammatory Agents; D016588:Anticarcinogenic Agents; D005765:Gastrointestinal Agents